Glycosaminoglycans: from “cellular glue” to novel therapeutical agents  by Karamanos, Nikos K & Tzanakakis, George N
Current Comments
Glycosaminoglycans: from ‘‘cellular glue’’ to novel therapeutical
agents§
Nikos K Karamanos and George N Tzanakakis
Current Opinion in Pharmacology 2012, 12:220–222
Available online 9th February 2012
1471-4892
# 2011 Elsevier Ltd. 
DOI 10.1016/j.coph.2011.12.003
Nikos K Karamanos
University of Patras, Greece
Nikos Karamanos is a Professor of Biochemistry at the
University of Patras. He has carried out predoctoral and
postdoctoral research at Karolinska Institute (School of
Medicine, Sweden). Currently he is on the editorial boards of
several journals among them the Journal of Biological
Chemistry and Current Medicinal Chemistry, and serves as
Academic Editor of Plos One. His research is focused on
biological matrix effectors (proteoglycans,
glycosaminoglycans, metalloproteinases and glycoproteins)
and involves matrix pathobiology, cell signaling and gene
expression, pharmacological targeting, drug preclinical
evaluation, mimetic cellular paracrine models and
development of bioanalytical assays.
George N Tzanakakis
University of Crete, Greece
George Tzanakakis is currently a Professor of Anatomy-
Histology at the Medical School, University of Crete, Heraklion.
Originally he trained as pathologist at the Medical School,
University of Patras, and clinical cytologist at the Karolinska
Institute, Stockholm. He has scientifically participated, during
more than two decades, in the fields of tumor biology,
extracellular matrix pathobiology and growth factors’ signaling.
His scientific interests are specifically focused on the study of
proteoglycans and glycosaminoglycans structure and function
in malignant cellular milieu and the possibility of their
therapeutic applications as anti-cancer agents.
Current Comments are a rapid outlet for scientific
opinions on a topic of general interest.
Glycosaminoglycans (GAGs), linear macromolecular heteropolysacchar-
ides consisting of disaccharide repeating units, are classified into several
types. Hexuronic acid based GAGs include heparin (HP) and heparan
sulfate (HS), which are glucosamine containing sulfated GAGs, chon-
droitin and dermatan sulfates (CS and DS), based on galactosamine,
and hyaluronan which is a glucosamine based non-sulfated GAG. Keratan
sulfate is a non-hexuronic acid galactose containing sulfated GAG. They
were originally defined as inert ‘glue’ surrounding the cells and were
thus positioned on the side-track of ‘cutting-edge’ research efforts for
decades. During the last years, however, a huge leap in the field has
been accomplished and these macromolecules are now recognized as
essential players in critical biological processes regulating cellular proper-
ties; tissue development and remodelling; homeostasis; and disease
progression.
The unique structural characteristics at the level of sulfation within the
GAG chains are closely related with their diverse functions. The evidence
that GAGs have a key role in various pathological conditions, have led to the
conclusion that understanding the changes in GAG expression and fine
structure that occur in disease may lead to opportunities to develop inno-
vative and selective therapies (reviewed by [1]). This has initiated numerous
and novel approaches to exploit pluripotent characteristics of GAGs in the
ongoing battle against disease.
Acknowledgement of GAGs as potential therapeutic agents dates from the
beginning of 19th century. The highly sulfated, free GAG, heparin was
discovered in 1916 to have potent anticoagulation properties, whereas the
first clinical trials in 1941, introduced heparin as a pioneer drug in the field of
GAG therapeutics. The extensive use of this wonder agent, has promoted
the progress and development of vascular and cardiac surgery, the extra-
corporeal circulation, the haemodialysis, the organ transplantation and the
treatment and prevention of arterial and venous thromboembolism. This
impressive track history is based on heparins’ ability to interact with
antithrombin III and heparin cofactor II, promoting their activation and
increasing their ability to inhibit thrombin.
Frequent use of heparin in the treatment of cancer-associated thromboem-
bolism initially pointed out its anti-cancer potential. Accumulating clinical
evidence indicates that cancer patients treated with unfractionated and low-
molecular weight heparin (LMWHP) survive longer than patients treated by
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Current Comments Karamanos and Tzanakakis 221other anticoagulants, especially patients in the early stage
of the disease. The non-anticoagulant activity of heparin
on metastasis includes the ability to inhibit cell–cell
interaction through blocking of P-selectin and L-selectin,
to inhibit the extracellular matrix enzyme heparanase, to
modulate the binding of growth factors involved in epi-
thelial to mesenchymal transition during tumor invasion
and to inhibit angiogenesis [2]. Notably, the inhibition of
melanoma cell adhesion and migration by LMWHP via
the PKCa/JNK signaling axis affecting actin cytoskeleton
changes opens another area in GAG therapeutics for the
future [3].
The extraordinary possibilities of GAG applications in
targeted disease treatment are further illustrated by the
ability of heparin to regulate processes correlated with
inflammation. Heparin participates in the regulation of
the inflammatory response by inhibiting the influx of
neutrophils into certain tissues and attenuating T-cell
trafficking, partly by an inhibitory effect on the hepar-
anase secreted by T-cells. In the lung, it has been
suggested that inhibition of the interaction between
pro-inflammatory cytokines and membrane-associated
GAGs by heparin may provide a mechanism for indu-
cing clinically useful immunosuppression (reviewed
by [4]).
Structurally similar to heparin, HS, which in the cellular
milieu is bound into proteoglycans (PGs), facilitates both
angiogenesis and the activity of the HS-cleaving hepar-
anase. The HS side chains of PGs present in basal
membrane contribute not only to storing and preserving
the biological activity of various HS-binding cytokines
and growth factors, but also in presenting them in a more
‘active conformation’ to their cognate receptors. Abnor-
mal expression or deregulated function of these PGs
affect cancer and angiogenesis, and are critical for the
evolution of the tumor microenvironment [5]. Further-
more, GAGs as binding partners for matrix metallopro-
teinases and protease inhibitors, regulate the proteolytic
microenvironment of tumors, thus modulating metastatic
spread.
Heparan sulfate mimetics, that have been developed to
inhibit these processes, are currently undergoing formal
preclinical development as a novel treatment for
advanced cancer [6]. Heparan sulfate membrane PGs
may also be a scaffold that facilitates the interaction of
intracellular pathogens with secondary receptors that
mediate host cell entry, a key step in the infection
process. Consistent with this mechanism, application
of HS or heparin as well as modulation of host cell
membrane HS inhibits microbial attachment and entry
[7].
Chondroitin and dermatan sulfates also have intriguing
biological activities, which in turn should help thewww.sciencedirect.com development of CS/DS-based therapeutics (reviewed
by [8]). In the milieu of cancer deregulation, the
observation that CS is overexpressed in several highly
metastatic tumors led to the suggestion that CS
may well be used as a target for the selective delivery
of anti-cancer drugs by polyethylene glycol-coated
liposomes.
Hyaluronan matrices are ubiquitous in normal and patho-
logical biological processes. Indeed, many cell stress
responses initiate the synthesis of a monocyte-adhesive
hyaluronan extracellular matrix, which forms a central
focus for subsequent inflammatory processes that are
modulated by the dialogue between the matrix and the
inflammatory cells [9].
The specific physicochemical properties of GAGs
allow these molecules to support and re-establish struc-
tural tissue homeostasis which resulted in their exten-
sive use in orthopaedic clinical practice as well as in
reconstructive and cosmetic surgery. Chondroitin sul-
fate belongs to the oral symptomatic slow-acting drugs
for the treatment of osteoarthritis. The evidence for
clinical efficacy of oral CS as a drug comes from sets of
clinical trials which document their good tolerability
and safety aspects [10]. Moreover, HA has been exten-
sively used in both reconstructive and cosmetic surgery
due to its effectiveness, ease of administration, and
safety profile.
The endeavours of the ‘wonder’ drug heparin are well
known. Encouraging studies, briefly outlined above,
strongly indicate the potential use of GAGs as potent
therapeutic agents in this promising field of targeted
disease therapy.
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